Danaher (DHR) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue declined 3.0% year-over-year to $5.74 billion, with core sales down 3.5%, mainly due to declines in Biotechnology and Life Sciences, partially offset by Diagnostics growth; adjusted diluted EPS was $1.72.

• Operating profit margin improved to 20.3% in Q2 2024 from 19.7% in Q2 2023, driven by cost structure improvements and lower inventory write-offs.

• Free cash flow was $1.1 billion for the quarter, down 14.5% year-over-year, with a free cash flow-to-net income conversion ratio of 1.25x.

• Bioprocessing and diagnostics, particularly Cepheid, showed strong momentum and market share gains in molecular testing.

• The company repurchased approximately 19 million shares through Q2 and July, authorizing a new 20 million share repurchase program.

Financial highlights

• Q2 2024 sales were $5.74 billion, with gross profit margin at 59.7% and adjusted operating profit margin at 27.3%.

• Net earnings from continuing operations were $907 million, with a margin of 15.8%.

• Adjusted EBITDA margin increased to 30.4% from 29.5% year-over-year.

• Operating profit (GAAP) was $1.17 billion, nearly flat year-over-year.

• Free cash flow conversion ratio was 1.25x net earnings from continuing operations.

Outlook and guidance

• Q3 and full-year 2024 core revenue expected to decline low single digits year-over-year; adjusted operating margin guidance for Q3 is 26% and for full year is 29%.

• Bioprocessing business expected to decline low single digits for 2024, with high single-digit or better growth as the year ends.

• Biotechnology core revenue expected to gradually improve through 2024.

• Effective tax rate for the remainder of 2024 projected at approximately 17.5%.

• Sufficient liquidity to fund operations, acquisitions, dividends, and share repurchases.